151 related articles for article (PubMed ID: 36114029)
1. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
3. NLRP12 is a prognostic biomarker and correlated with immune infiltrates in epithelial ovarian cancer.
Ma R; Tang Z; Wang J
J Gene Med; 2024 Jan; 26(1):e3585. PubMed ID: 37926491
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
5. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
6. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
7. Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
Natoli M; Gallon J; Lu H; Amgheib A; Pinato DJ; Mauri FA; Marafioti T; Akarca AU; Ullmo I; Ip J; Aboagye EO; Brown R; Karadimitris A; Ghaem-Maghami S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436485
[TBL] [Abstract][Full Text] [Related]
8. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.
Yang Z; Yang X; Xu S; Jin P; Li X; Wei X; Liu D; Huang K; Long S; Wang Y; Sun C; Chen G; Hu J; Meng L; Ma D; Gao Q
Mol Cancer; 2017 Oct; 16(1):163. PubMed ID: 29041931
[TBL] [Abstract][Full Text] [Related]
10. Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis.
Chen LY; Huang RL; Su PH; Chu LH; Weng YC; Wang HC; Lai HC; Wen KC
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563509
[TBL] [Abstract][Full Text] [Related]
11. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
12. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer.
Yue H; Li W; Chen R; Wang J; Lu X; Li J
Gynecol Oncol; 2021 Feb; 160(2):530-538. PubMed ID: 33317907
[TBL] [Abstract][Full Text] [Related]
13. Four genes relevant to pathological grade and prognosis in ovarian cancer.
Pan X; Chen Y; Gao S
Cancer Biomark; 2020; 29(2):169-178. PubMed ID: 32444534
[TBL] [Abstract][Full Text] [Related]
14. FPR2 participates in epithelial ovarian cancer (EOC) progression through RhoA-mediated M2 macrophage polarization.
Xie X; He J; Wang Q; Liu Y; Chen W; Shi K
J Ovarian Res; 2021 Dec; 14(1):177. PubMed ID: 34930387
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic and membranous receptor-binding cancer antigens expressed on SiSo cells (RCAS1) immunoreactivity in epithelial ovarian cancer cells represent differing biological function of RCAS1.
Szubert S; Jozwicki W; Wicherek L; Koper K
Folia Histochem Cytobiol; 2019; 57(3):116-126. PubMed ID: 31388982
[TBL] [Abstract][Full Text] [Related]
17. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
18. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment.
Mao TL; Fan MH; Dlamini N; Liu CL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638541
[TBL] [Abstract][Full Text] [Related]
19. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
[TBL] [Abstract][Full Text] [Related]
20. High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer.
Deng Y; Liu L; Feng W; Lin Z; Ning Y; Luo X
Recent Pat Anticancer Drug Discov; 2021; 16(4):533-539. PubMed ID: 34551701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]